GeneDx Holdings Corp. Class Action Lawsuit – WGS

Introduction

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS), CEO Katherine Stueland, and CFO Kevin Feeley on behalf of investors who purchased WGS common stock between April 16, 2025 and May 4, 2026. The complaint alleges that defendants made materially false and misleading statements about the impact and viability of GeneDx's acquisition of Fabric Genomics, an AI-driven genomic interpretation firm acquired for up to $51 million, repeatedly touting the deal as a catalyst for recurring revenue streams, expanded addressable markets, and reduced costs. According to the complaint, the truth emerged on May 4, 2026, when GeneDx disclosed that it had missed revenue estimates for both its exome and genome lines, slashed full-year revenue guidance by approximately 15%, and disclosed a $31.2 million impairment charge directly attributable to Fabric. The complaint alleges that, following these disclosures, WGS stock declined $33.42 per share, or 49.20%, causing losses to investors who purchased at allegedly inflated prices during the Class Period.

Company Profile

GeneDx Holdings Corp. is a genomics company specializing in genetic testing services for diagnosing pediatric and rare diseases, with a particular focus on whole genome sequencing and whole exome sequencing for inherited disorders. The Company is headquartered in Stamford, Connecticut and trades on the NASDAQ under the ticker symbol WGS.

Class Period

April 16, 2025 – May 4, 2026

Investors who purchased or acquired GeneDx Holdings Corp. (WGS) common stock during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint centers on GeneDx's April 16, 2025 announcement that it had agreed to acquire Fabric Genomics, an Oakland, California-based firm specializing in AI-driven genomic interpretation, in a deal worth up to $51 million. At the time, GeneDx stated that the acquisition would expand the company's addressable market with "multiple scalable revenue streams" and described Fabric's software as capable of transforming "static data into a dynamic, recurring revenue-generating platform." When the acquisition closed on May 5, 2025, CEO Katherine Stueland reinforced these claims, stating the deal would "unlock recurring software-based revenue streams through Fabric's interpretation as-a-service model."

According to the complaint, defendants continued making optimistic statements about Fabric's integration and financial contribution throughout the Class Period. During the Q2 2025 Earnings Call on July 29, 2025, Stueland described Fabric as "off to a great start," stating the team was "on track with our plan this year in terms of their revenues, their gross margins" and highlighting plans to hire international sales representatives to drive Fabric utilization globally. CFO Kevin Feeley stated during the same call that "there was room to run in terms of reducing COGS in the future by combining the best of capability between GeneDx and Fabric." At an industry conference on January 14, 2026, Stueland discussed how Fabric would enable GeneDx to scale globally, describing a vision where the company's interpretation platform could be deployed "wherever there is a sequencer being bought anywhere in the world." On that same occasion, she reiterated the company's full-year 2026 revenue guidance of $540 million to $555 million with adjusted gross margins of at least 70%.

The complaint alleges that these statements were materially false and misleading because defendants knew of, or recklessly disregarded, significant problems with Fabric's viability that would negatively impact GeneDx's overall business and operations. While the company's core genomic testing segments continued to grow through 2025, pushing WGS stock to a Class Period high of $167.52, Fabric allegedly failed to meet its stated goals of driving growth and instead dragged down the company's financial performance. The complaint contends that the company's statements concerning its business, operations, and prospects lacked a reasonable factual basis, and that WGS common stock traded at artificially inflated prices as a result.

The complaint further details how defendants' financial disclosures shifted over successive quarters, with key metrics such as gross margins and reimbursement rates declining while defendants continued to project confidence in the company's trajectory. During the Q3 2025 Earnings Call, Feeley reported adjusted gross margins of 74% and an average reimbursement rate exceeding $3,800. By the Q4 2025 Earnings Call on February 23, 2026, he acknowledged that "mix dynamics had fluctuated" and the average reimbursement rate had fallen to approximately $3,750, yet he assured investors that "the long-term trend is up and durable" and characterized the company's gross margin guidance as "a fairly conservative view."

The Truth Emerges

The complaint alleges that the truth about GeneDx's deteriorating business fundamentals and the underperforming Fabric acquisition emerged after hours on May 4, 2026, when the company reported first quarter 2026 financial results. During the earnings call, CEO Stueland stated that it had "become increasingly clear that Fabric was best suited only for international markets," that the company had "much left to do" to fully integrate Fabric into GeneDx, and that the company was lowering its expectations for Fabric's revenue contribution in 2026. The company also disclosed that it had taken a $31.2 million impairment charge, writing down goodwill and other intangible assets directly attributable to Fabric.

The disclosures extended well beyond Fabric. CFO Feeley revealed that the blended average reimbursement rate had fallen to approximately $3,300, roughly $200 below expectations and a steep decline from the $3,800 reported just two quarters earlier. The company's adjusted gross margin dropped from 74% to 69%, and GeneDx slashed its full-year 2026 revenue guidance from $540 to $555 million down to $475 to $490 million, a reduction of approximately 15%. The company reported misses in both its exome and genome revenue lines. As Canaccord Genuity analyst Kyle Mikson wrote following the disclosures, the results "appeared to reflect the reversal of important growth drivers" and the problems appeared "more systemic in nature," raising questions about when GeneDx's core whole exome and whole genome sequencing business would "recover to historical growth rates."

Market Reaction

The market reaction to GeneDx's May 4, 2026 after-hours disclosures was severe. WGS stock, which had closed at $67.93 per share the day before the earnings release, declined by $33.42 per share, a drop of 49.20%. This collapse came after WGS had traded as high as $167.52 during the Class Period, a price that the complaint alleges was artificially inflated by defendants' materially false and misleading statements about the company's business, operations, and prospects. The complaint cites the magnitude of the single-day decline as support for its allegation that investors had not been told the full truth about GeneDx’s business and Fabric’s impact.

Next Steps

●       Lead Plaintiff Deadline: August 3, 2026

●       After the lead plaintiff deadline, the Court is expected to consider any lead plaintiff motions and appoint lead plaintiff and lead counsel.

●       Defendants may file a motion to dismiss the complaint.

●       If the case proceeds, the Court may later consider class certification.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Check Eligibility